Latest Breaking News On - ஒன்றுபட்டது மாநிலங்களில் இராணுவம் மருத்துவ ஆராய்ச்சி - Page 4 : comparemela.com

by WRAL TechWire May 26, 2021 . DURHAM –Inhalon Biopharma is developing a “muco-trapping” antibody platform that could be used to treat acute respiratory infections, including COVID-19, and the Durham-based startup has now been awarded a $7 million contract by the United States Army Medical Research & Development Command (USAMRDC). The contract will allow the company to conduct a placebo-controlled Phase 1 and Phase 2a study of its technology in COVID-19 outpatients, the company shared in a statement. The technology, currently designated IN-006, is described by the company as a potent, neutralizing monoclonal antibody that is being investigated as a possible treatment for COVID-19. The company expects results of the study in 2022.

John whelanSam laiInhalon biopharmaUnited states army medical research development commandJohns hopkins universityUniversity of north carolina at chapel hillUnited states army medical researchDevelopment commandProfessor sam laiNorth carolinaChapel hillJohns hopkinsBreakout labsஜான் சக்கரம்சாம் லாய்ஜான்ஸ் ஹாப்கின்ஸ் பல்கலைக்கழகம்